

Product Data Sheet

Inbakicept

Cat. No.:	HY-P99661
CAS No.:	2135939-52-3
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

Description	Inbakicept, also known as N-803 (Nogapendekin alfa inbakicept), contains the IL-15 cytokine antibody Nogapendekin alfa (HY-P99759). Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). Inbakicept also increases degranulation and IFNγ production in cells ^[1] .		
IC ₅₀ & Target	IL-15Rα		
In Vitro	Inbakicept (0.01-1 nM; 20 hr) enhances human NK cell cytotoxicity and increases cytotoxic effector molecule expression ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity Assay ^[1]		
	Cell Line:	Daudi, Raji, CD19 ⁺ FL cells	
	Concentration:	0.01 nM, 0.1 nM, and 1 nM	
	Incubation Time:	20 hours	
	Result:	Increased the human NK cell cytotoxicity on Daudi, Raji, CD19 ⁺ FL cells.	
In Vivo	Inbakicept (0.2 mg/kg; i.v.; twice weekly, for 2 weeks) enhances rituximab-directed protection from a lethal Daudi lymphoma challenge in mouse model ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	SCID mice with Daudi models ^[1]	
	Dosage:	0.02 mg/kg, 0.05 mg/kg, 0.1 mg/kg, and 0.2 mg/kg	
	Administration:	Intravenous injection; twice weekly, for 2 weeks	
	Result:	Enhanced rituximab-directed control of Raji lymphoma challenge.	

REFERENCES

[1]. Rosario M, et al. The IL-15-Based ALT-803 Complex Enhances FcyRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. Clin Cancer Res. 2016 Feb 1;22(3):596-608.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA